Chapter 21
Neutralization of Th2 Cytokines in Therapy of Cardiovascular Pathology
A. Mandel, A. E. Bolton,
A. E. Bolton
Search for more papers by this authorA. Mandel, A. E. Bolton,
A. E. Bolton
Search for more papers by this authorBook Editor(s):Ronald Ross Watson,
Douglas F. Larson,
Ronald Ross Watson
Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona
Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA
Search for more papers by this authorDouglas F. Larson
Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA
Search for more papers by this authorFirst published: 30 August 2007
Summary
This chapter contains section titled:
-
Introduction
-
The role of the immune system in cardiovascular pathology
-
The endothelium, immunology, and cardiovascular disease
-
IL-4 in cardiovascular disease
-
IL-6 in cardiovascular disease
-
IL-3, IL-5, and IL-13 in cardiovascular disease
-
Conclusion
-
References
References
- Seder RA Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Ann Rev Immunol 1994; 12: 635–73.
- Borish LC Steinke JW II. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111 (suppl 2): S460–75.
- Lorentz A Wilke M Sellge G et al. IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J Immunol 2005; 174 (11): 6751–6.
- Yano S Ghosh P Kusaba H Buchholz M Longo D.L. Effect of promoter methylation on the regulation of IFN-gamma gene during in vitro differentiation of human peripheral blood T cells into a Th2 population. J Immunol 2003; 171 (5): 2510–6.
- Gardner EM Murasko D.M. Age-related changes in type 1 and type 2 cytokine production in humans. Biogeron-tology 2002; 3 (5): 271–90.
-
Hamelmann E
Gelfand E.W.
IL-5-induced airway eosinophilia—the key to asthmå.
Immunol
2001;
179:
182–91.
10.1034/j.1600-065X.2001.790118.x Google Scholar
- Miller A.L. The etiologies, pathophysiology, and alternative/complementary treatment of asthma. Altern Med Rev 2001; 6 (1): 20–47.
- Saito S. Cytokine network at the feto-maternal interface. J Reprod Immunol 2000; 47 (2): 87–103.
- Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000; 85 (1): 9–18; quiz 18, 21.
- Trinchieri G Peritt D Gerosa F. Acute induction and priming for cytokine production in lymphocytes. Cytokine Growth Factor Rev 1996; 7 (2): 123–32.
- Wood PR Seow H.F. T cell cytokines and disease prevention. Vet Immunol Immunopathol 1996; 54 (1–4): 33–44.
- Mosmann TR Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–46.
- O'Garra A Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol December 2000; 10 (12): 542–50.
- Businaro, R, Digregorio, M, Rigano, R et al. Morphological analysis of cell subpopulations within carotid atherosclerotic plaques. Ital J Anat Embryol 2005; 110 (2, suppl 1): 109–15.
- Huang AL Vita J.A. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc Med 2006; 16 (1): 15–20.
- Prabhu S.D. Cytokine-induced modulation of cardiac function. Circ Res 2004; 95 (12): 1140–53.
- Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5.
- Matzinger P. An innate sense of danger. Ann N Y Acad Sci 2002; 961: 341–2.
- Akira S Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85 (2): 85–95.
- Weyand CM Ma-Krupa W Pryshchep O Groschel S Bernardino R Goronzy J.J. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 2005; 1062: 195–208.
- Matzinger P. An innate sense of danger. Semin immunol 1998; 10: 399–415.
- Liao D-F Jin Z-G Baas A. et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189–96.
- Xu Q Schett G Perschinka H et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000; 192: 14–20.
- Watanabe M Watanabe S Hara Y et al. ICOS-mediated costimulation on Th2 differentiation is achieved by the enhancement of IL-4 receptor-mediated signaling. J Immunol 2005; 174 (4): 1989–96.
- Coyle AJ Lehar S Lloyd C et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13 (1): 95–105.
- Tesciuba AG Subudhi S Rother R. et al. Inducible costimulatorregulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol 2001; 167 (4): 1996–2003.
- McAdam, AJ, Greenwald RJ Levin M. et al. ICOSiscriti-cal for CD40-mediated antibody class switching. Nature 2001; 409 (6816): 102–5.
- Das G Augustine MM Das J Bottomly K Ray P Ray A. An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel disease. Proc Natl Acad Sci U S A 2003; 100 (9): 5324–9.
- Takeda K Tanaka T Shi W et al. Essential role of Stat6 in IL-4 signalling. Nature 1996; 380 (6575): 627–30.
- Shimoda K van Deursen J Sangster M. et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380 (6575): 630–3.
- Ma-Krupa W Jeon MS Spoerl S Tedder TF Goronzy JJ Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med January 19, 2004; 199 (2): 173–83.
- Kalayoglu MV Hoerneman B LaVerda D Morrison SG Morrison RP Byrne G.I. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180 (3): 780–90.
- Brune IB Wilke W Hensler T Holzmann B Siewert J.R. Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999; 177 (1): 55–60.
- Souza VM Jacysyn JF Macedo M.S. IL-4 and IL-10 are essential for immunosuppression induced by high molecular weight proteins from Ascaris suum. Cytokine 2004; 28 (2): 92–100.
- Morris SC Orekhova T Meadows MJ Heidorn SM Yang J Finkelman F.D. IL-4 induces in vivo production of IFN-gamma by NK and NKT cells. J Immunol 2006; 176 (9): 5299–305.
- Nandakumar KS Holmdahl R. Arthritis induced with cartilage-specific antibodies is IL-4-dependent. Eur J Immunol 2006; 36 (6): 1608–18.
- Ohtsuka T Inoue K Hara Y et al. Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy. Eur J Heart Fail June 2005; 7 (4): 689–95.
- Walch L Massade L Dufilho M Brunet A Rendu F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and mono-cyte chemoattractant protein-1 expression. Atherosclerosis 2006; 187 (2): 285–91.
- Lee YW Kuhn H Kaiser S Hennig B Daugherty A Toborek M. Interleukin 4 induces transcription of the 15-lipoxygenase I gene in human endothelial cells. J Lipid Res May 2001; 42 (5): 783–91.
- Lee YW Hirani A.A. Role of interleukin-4 in atherosclerosis. Arch Pharm Res 2006; 29 (1): 1–15.
- Lee YW Kuhn H Hennig B Toborek M. IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett 2000; 485 (2–3): 122–6.
- Chan WL Pejnovic N Liew TV Hamilton H. Predominance of Th2 response in human abdominal aortic aneurysm: mistakenidentity for IL-4-producing NK and NKT cells. Cell Immunol February 2005; 233 (2): 109–14.
- Chen B Tsui S Boeglin WE Douglas RS Brash AR Smith T.J. Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem July 7, 2006; 281 (27): 18296–306.
- Afanasyeva M Wang Y Kaya Z et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001; 159 (1): 5–12.
- Kuethe F Braun RK Foerster M et al. Immunopatho-genesis of dilated cardiomyopathy. Evidence for the role of TH2-type CD4+T lymphocytes and association with myocardial HLA-DR expression. J Clin Immunol January 2006; 26 (1): 33–9.
- Cunningham M.W. Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis. Am J Pathol 2001; 159 (1): 5–12.
- Poulin LF Richard M Le Moine A et al. Interleukin-9 promotes eosinophilic rejection of mouse Heart allo-grafts. Transplantation August 15, 2003; 76 (3): 572–7.
- Van Hoffen E Van Wichen D Stuij I et al. In situ expression of cytokines in human Heart allografts. Am J Pathol December 1996; 149 (6): 1991–2003.
- Zambon A Gervois P Pauletto P Fruchart JC Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol May 2006; 26 (5): 977–86.
- Lobbes MB Lutgens E Heeneman S et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis July 2006; 187 (1): 18–25.
- Omoigui S. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses 2005; 65 (3): 559–69.
- Tanko LB Christiansen C. Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy. Climacteric July 2006; 9 (3): 169–80.
- Kanda T Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J March 2004; 45 (2): 183–93.
-
Carter A.M.
Inflammation, thrombosis and acute coronary syndromes.
Diab Vasc Dis Res
2006;
2
(3):
113–21.
10.3132/dvdr.2005.018 Google Scholar
- Torre-Amione G. Immune activation in chronic Heart failure. Am J Cardiol 2005; 95(11A): 3C–8C.
- Hogye M Mandi Y Csanady M Sepp R Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol July 15, 2004; 94 (2): 249–51.
- Buzas K Megyeri K Hogye M Csanady M Bogats G Mandi Y. Comparative study of the roles of cy-tokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur Cytokine Netw January–March 2004; 15 (1): 53–9.
- Weisensee D Bereiter-Hahn J Schoeppe W Low-Friedrich I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol July 1993; 15 (5): 581–7.
- Fox CS Guo CY Larson M. et al. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol May 15, 2006; 97 (10): 1502–5.
- Nesher N Frolkis I Vardi M et al. Higher levels of serum cytokines and myocardial tissue markers during on-pump versus off-pump coronary artery bypass surgery. J Card Surg 2006; 21 (4): 395–402.
- Ustunsoy H Sivrikoz MC Tarakcioglu M Bakir K Guldur E Celkan M.A. The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J Card Surg January–February 2006; 21 (1): 57–61.
- Franke A Lante W Fackeldey V et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know. Eur J Cardiothorac Surg 2005; 28 (4): 569–75.
- Deng MC Plenz G Labarrere C et al. The role of IL6 cytokines in acute cardiac allograft rejection. Transpl Immunol May 2002; 9 (2–4): 115–20.
- Das U.N. Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period. J Assoc Physicians India February 2006; 54: 133–42.
- Sjoholm A Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev January–February 2006; 22 (1): 4–10.
- Kazama R Okura Y Hoyano M et al. Therapeutic role of pericardiocentesis for acute necrotizing eosinophilic myocarditis with cardiac tamponade. Mayo Clin Proc 2003; 78 (7): 901–7.
- Smith CR Mohanakumar T Shimizu Y et al. Brief cy-closporine treatment prevents intrathymic (IT) tolerance induction and precipitates acute rejection in an IT rat cardiac allograft model. Transplantation January 27, 2000; 69 (2): 294–9.
- Zweifel M Hirsiger H Matozan K Welle M Schaffner T Mohacsi P. Mast cells in ongoing acute rejection: increase in number and expression of a different phenotype in rat Heart transplants. Transplantation 2002; 73 (11): 1707–16.
- Foteinos G Afzal AR Mandal K Jahangiri M Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 2005; 112 (8): 1206–13.
- Mentink-Kane MM Wynn T.A. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev December 2004; 202: 191–202.
- Ma B Liu W Homer R. et al. Role of CCR5 in the patho-genesis of IL-13-induced inflammationand remodeling. J Immunol April 15, 2006; 176 (8): 4968–78.
- Kofler S Nickel T Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) March 2005; 108 (3): 205–13.
- Mombouli JV Vanhoutte P.M. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol January 1999; 31 (1): 61–74.
- Iversen PO Nicolaysen A Kvernebo K Benestad HB Nicolaysen G. Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch December 1999; 439 (1–2): 93–100.
- Beutelspacher SC Tan PH McClure MO Larkin DF Lechler RI George A.J. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 2006; 6 (6): 1320–30.
- Karmann K Min W Fanslow WC Pober J.S. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and inter-leukin 1. J Exp Med 1996; 184: 173–82.
- Kunitomi A Hori T Imura A Uchiyama T. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J Leukoc Biol 2000; 68: 111–8.
- Chen Z Marsden PA Gorczynski R.M. Cloning and characterization of the human CD200 promoter region. Mol Immunol 2006; 43 (6): 579–87.
- Klingenberg R Autschbach F Gleissner C et al. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro. Eur J Immunol 2005; 35 (6): 1712–21.
- Janssens S Beyaert, R Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16 (4): 637–46.
- Paterson HM Murphy TJ Purcell E. et al. Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol 2003; 171 (3): 1473–83.
- Pober JS Cotran R.S. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537–44.
- Pober JS Orosz CG Rose ML Savage C.O. Can graft endothelial cells initiate a host anti-graft immune response. Transplantation 1996; 61 (3): 343–9.
- Vora M Yssel H de Vries J Karasek M. Antigen presentation by human dermal microvascular endothelial cells. Immunoregulatory effect of IFN–y and IL-10. J Immunol 1994; 152: 5734–41.
- Vichchatorn P Wongkajornsilp A Petvises S Tangpradabkul S Pakakasama S Hongeng S. Dendritic cells pulsed with total tumor RNA for activation NK-like T cells. J Neurooncol November 2005; 75 (2): 111–8.
- Pernis A Witthuhn B Keegan A. et al. Interleukin 4 signals through two related pathways. Proc Natl Acad Sci U S A 1995; 92 (17): 7971–5.
- Kalayoglu MV Hoerneman B LaVerda D Morrison SG Morrison RP Byrne G.I. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180 (3): 780–90.
- Drory Y Turetz Y Hiss Y et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68: 1388–92.
- Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma. Trial listed on FDA Clinicaltrials.gov website. Accessed June 2006. http:// www.clinicaltrials.gov/ct/show/NCT00001909?order=9.
- Recombinant Human IL-4 Receptor Used in Treatment of Asthma. Trial listed on FDA Clinicaltrials.gov website. Accessed June 2006. http://www.clinicaltrials.gov/ct/show/NCT00017693?order=4.
- Borish LC Nelson HS Corren J et al. for IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol June 2001; 07 (6): 963–70.
- Kanai K Asano K Watanabe S Kyo Y Suzaki H. Epinas-tine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol 2006; 140 (1): 43–52.
- Nishikubo K Murata Y Tamaki S et al. A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. Gene Ther December 10, 2003; 26: 2119–25.
- Zavorotinskaya T Tomkinson A Murphy J.E. Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13. Mol Ther February 7, 2003; 2: 155–62.
- Rincon M Anguita J Nakamura T Fikrig E Flavell R.A. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185 (3): 461–9.
- Diehl S Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002; 39 (9): 531–6.
- Fisman EZ Benderly M Esper R. et al. Interleukin-6 and the Risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006; 98 (1): 14–8.
- Khreiss T Jozsef L Potempa LA, Filep J.G. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110 (17): 2713–20.
- Simon DI Chen Z Xu H et al. Platelet glycoprotein Ib is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193–204.
- Santoso S Sachs UJH Kroll, H et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679–91.
- Ridker PM Morrow D.A. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21 (3): 315–25.
- Bassuk SS Rifai N Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 8: 439–93.
- Nakahara, H, Song J Sugimoto M. et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum June 2003; 48 (6): 1521–9.
- Press release dated April 282006: “Actemrå,” a humanized anti-human IL-6 receptor monoclonal antibodyfiled for rheumatoid arthritis in japan. http://www.chugai-pharm.co.jp/generalPortal/pages/detailTypeTable.jsp;jsessionid=BWKJQI3OAGGMICSSUIHSFEQ?documentId=doc_6921&lang=en.
- Chugai development pipeline as of April 252006. Chugai website. Accessed June2006. http://www.chugai-pharm.co.jp/pdf/pipeline/english/060425ePipeline.pdf.
- A study to assess the safety and efficacy of tocilizumab in patients with active rheumatoid arthritis. Clinical trial listed on FDA Clinical Trials.gov website. Accessed June 2006. http://www.clinicaltrials.gov/ct/show/NCT00109408?order=1.
- Nishimoto N Yoshizaki K Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum June 2004; 50 (6): 1761–9.
- Choy EH Isenberg DA Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum December 2002; 46 (12): 3143–50.
- Nishimoto N Kanakura Y Aozasa K et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood October 15, 2005; 106 (8): 2627–32.
- Yokota S Miyamae T Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum March 2005; 52 (3): 818–25.
- Monoclonal Antibody Treatment for Systemic Lupus Erythematosus. Clinical trial listed on FDA Clinical Trials.gov website. Accessed June 2006. http:// www.clinicaltrials.gov/ct/show/NCT00046774?order=4.
- CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer. Clinical trial listed on FDA Clinical Trials.gov website. Accessed June 2006. http://www.clinicaltrials.gov/ct/gui/show/NCT00311545; jsessionid=1AA9B3B8E120F916669213EE5817223D? order=36.
- van Zaanen HC Koopmans RP Aarden L. et al. Endogenous interleukin 6production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. Clin Invest September 15, 1996; 98 (6): 1441–8.
- Callisto Pharmaceuticals website. Accessed June 2006. http://www.calisto-pharma.com/.
- Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma. Trial listed on FDA clin-icaltrials.org website. Accessed June 2006. http://www.clinicaltrials.gov/ct/show/NCT00086216?order=2.
- Atiprimod in Treating Patients With Refractory or Relapsed Multiple Myeloma. Trial listed on FDA clinicaltrials.org website. Accessed June 2006. http:// www.clinicaltrials.gov/ct/show/NCT00301977?order=1.
- Olsen EG Spry C.J. Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis January–February 1985; 27 (4): 241–54.
- Zurawski G de Vries J.E. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 1994; 12 (2): 169–74.
- Deswal A Bozkurt B Seta Y et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced Heart failure. Circulation 1999; 99: 3224–6.
- Mann DL NcNurray JJV Packer M et al. Targeted an-ticytokine therapy in patients with chronic Heart failure. Results of the randomised etanercept worldwide evaluation (RENEWAL). Circulation 2004; 109: 1594–602.
